Fox Chase Cancer Center News

September 20, 2021

Fox Chase Cancer Center Holds Paws for the Cause Dog Walk to Benefit Cancer Research

PHILADELPHIA (September 20, 2021)—Fox Chase Cancer Center will hold its 22nd annual Paws for the Cause dog walk to benefit cancer research as an in-person event this year, along with a two-week virtual event. Both events are hosted by the Fox Chase Board of Associates.

September 20, 2021

Fox Chase Cancer Center Welcomes Dr. Teresa Y. Lee

PHILADELPHIA (September 20, 2021) – Fox Chase Cancer Center is pleased to announce the hiring of Teresa Y. Lee, MD, PhD, as an assistant professor. Lee will focus on sarcoma and head and neck cancer.

September 17, 2021

Update on INVICTUS Trial Shows Improved Overall Median Survival in GIST Patients Using Ripretinib

PHILADELPHIA (September 17, 2021)—Results from the phase 3 INVICTUS clinical trial show that the drug ripretinib, also known by its brand name Qinlock, provides clinically meaningful improvement in overall median survival for patients with gastrointestinal stromal tumor (GIST) when compared with placebo.

September 15, 2021

Fox Chase Cancer Center’s Edna Cukierman Offers Commentary in Cancer Research ‘Landmark’ Article

PHILADELPHIA (September 15, 2021)—Fox Chase Cancer Center’s Edna “Eti” Cukierman, PhD, co-director of the Marvin & Concetta Greenberg Pancreatic Cancer Institute, recently published a “Landmark” commentary in the journal Cancer Research that explored the impact of a key study.

September 13, 2021

Researchers Find Early Stage Micropapillary Bladder Cancer Outcomes Similar to Late-Stage Conventional Urothelial Carcinoma

PHILADELPHIA (September 13, 2021)—A recent study from Fox Chase Cancer Center has found that in patients treated with radical cystectomy—removal of the bladder—those with cT1 micropapillary bladder cancer had similar or worse oncological outcomes compared with patients with cT2 conventional urothelial carcinoma.

September 11, 2021

Study Examines Cardiopulmonary Risks of Surgery in Patients With Prostate, Kidney Cancer

PHILADELPHIA (September 11, 2021)—In a recent study, Fox Chase Cancer Center researchers highlighted immediate cardiopulmonary risks associated with patients undergoing minimally invasive partial nephrectomy or prostatectomy for low-grade, low-stage disease. The study compared these risks with those associated with disease surveillance.

September 9, 2021

Fox Chase Cancer Center Presentations at the Virtual American Urological Association 2021 Annual Meeting

PHILADELPHIA (September 9, 2021)—As thousands of urologists from around the world gather virtually for the American Urological Association 2021 Annual Meeting, 10 Fox Chase Cancer Center faculty and students will present their research on a range of topics.

September 8, 2021

Fox Chase Researchers Identify Key Molecular Circuit Regulating Gut Immune Function

PHILADELPHIA (September 8, 2021)—Researchers at Fox Chase Cancer Center have identified a molecular circuit that plays a key role in regulating gut immunity. The researchers say the discovery could be a first step in the development of new therapies for colitis, inflammatory bowel disease (IBD), and other disorders.


Connect with Fox Chase